Abstract
Advanced or recurrent endometrial cancer is relatively uncommon and carries a poor prognosis. Recent decades have failed to witness a significant improvement in treatment outcomes for women with advanced disease, and mortality rates remain high. The precise role of surgical debulking, radiotherapy, hormonal therapy and cytotoxic chemotherapy in the treatment of advanced or recurrent disease is unclear. An improved understanding of the molecular pathology of endometrial cancer has allowed biologically relevant targets to be characterized and novel drugs are now being tested in early-Phase clinical trials. This review will present the evidence for the therapeutic options currently available to women with advanced or recurrent endometrial cancer and describe the progress that is being made in the field.
Financial & competing interests disclosure
The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.
No writing assistance was utilized in the production of this manuscript.